Placebo News and Research

RSS

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Anergis, a company focusing on proprietary allergy vaccines, today reported immunology data from the Phase IIb study of its lead compound AllerT.

21 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).

18 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

UTHealth researchers study how probiotic may help reduce gut inflammation in infants with colic

Researchers at The University of Texas Health Science Center at Houston have begun a study investigating whether a probiotic might be helpful in reducing gut inflammation in infants with colic.

17 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

Breast cancer patients receiving nerve block with general anesthesia have less cancer recurrence

Breast cancer patients who received the combination of a nerve block with general anesthesia for their breast cancer surgery had less cancer recurrence and were three times less likely to die than those who received only general anesthesia, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013

Placebo News and Research

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

Recombinant hormone could REPLACE calcium supplements

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

UTHealth researchers study how probiotic may help reduce gut inflammation in infants with colic

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

Breast cancer patients receiving nerve block with general anesthesia have less cancer recurrence

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

High doses of ADHD drugs may be effective for people with amphetamine dependency

Drug treatment ineffective for acute bronchitis

Pregabalin drug can help reduce incidence of chronic pain following cardiac surgery

Multi-drug therapy can benefit patients at higher risk for post-operative nausea and vomiting

Sanofi's Nasacort Allergy 24HR nasal spray receives FDA approval for over-the-counter use

Study: Statin do not improve VAP outcomes

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News